Efficacy and Safety of Ixekizumab in a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study in Paediatric Patients with Moderate-to-Severe Plaque Psoriasis (IXORA-PEDS).

CONCLUSIONS: IXE was superior to placebo in the treatment of moderate-to-severe paediatric psoriasis and the safety profile was generally consistent with that observed in adults. PMID: 32316070 [PubMed - as supplied by publisher]
Source: The British Journal of Dermatology - Category: Dermatology Authors: Tags: Br J Dermatol Source Type: research